Tesamorelin vs Sermorelin: Which GH Peptide Fits Which Goal

Tesamorelin and sermorelin are both growth hormone releasing hormone analogues. They bind the same receptor, they work through the same gland, and they produce the same class of downstream effect. On a mechanism diagram they are almost interchangeable. In every practical respect that matters, they are not.

The difference is not potency, though tesamorelin is the more durable signal. It is evidence. Tesamorelin carries two phase 3 trials and an approval built on a single, precisely measured endpoint. Sermorelin carries a handful of small studies, a discontinued approval from another era, and forty years of clinic use nobody has assembled into a dataset. Most of what separates them follows from that asymmetry rather than from anything at the receptor.

The Structural Difference That Explains Everything Else

Native human GHRH is a 44 amino acid peptide, and its biological activity lives almost entirely in the first 29 residues. Sermorelin is exactly that fragment, GHRH(1-29), with nothing added. It is the shortest sequence that still works.

Tesamorelin is a GHRH(1-44) analogue carrying a trans-3-hexenoyl group attached to the N-terminal tyrosine. That modification is not decorative. Dipeptidyl peptidase-4 attacks GHRH at the bond between the first two residues, and it does so fast enough that unmodified GHRH and sermorelin are largely gone within minutes of entering circulation. The hexenoyl group physically obstructs that cleavage site.

What the blocked cleavage buys

Sermorelin's circulating half-life sits around 11 to 12 minutes. Tesamorelin's runs closer to half an hour after subcutaneous injection. Both are short, but the ratio is roughly threefold and it changes the shape of the pituitary response.

A sermorelin dose produces a sharp pulse that resolves quickly. A tesamorelin dose keeps the receptor occupied long enough that the somatotrophs release across a wider window. Neither escapes negative feedback, which is the point of using a GHRH analogue in the first place, but tesamorelin gets more signal through before somatostatin closes the door. That is the mechanistic reason its IGF-1 response at standard dosing is the larger one.

What Each One Was Actually Approved For

Tesamorelin was approved under the brand name Egrifta for the reduction of excess visceral adipose tissue in people with HIV-associated lipodystrophy. That is the entire label. Everything outside that population is off-label extrapolation from a trial run in a specific group of patients.

Sermorelin was approved decades ago as Geref for diagnosing and treating growth hormone deficiency in children, and was withdrawn from the US market in the late 2000s for commercial reasons rather than safety ones. The distinction matters, because a drug pulled over safety and a drug pulled over sales volume leave very different marks on how you should read the gap in its file. Everything sermorelin is used for now runs through compounding pharmacies.

The Evidence Gap, Stated Plainly

Tesamorelin's phase 3 programme enrolled several hundred participants across two trials at 2mg daily for 26 weeks, with a 26 week extension after that. The primary endpoint was visceral adipose tissue measured by CT, which is about as objective a body composition measure as exists. Pooled, the drug produced roughly a 15 percent reduction in visceral fat while placebo arms drifted slightly upward. Triglycerides fell meaningfully. IGF-1 roughly doubled.

Sermorelin's adult evidence is thinner by an order of magnitude. The most useful data points come from small studies in older adults, where IGF-1 rises within about two weeks, lean mass increases in men at around 16 weeks, and skin thickness changes in both sexes. A separate short protocol at 2mg nightly for six weeks moved essentially nothing, which is a useful reminder that dose and duration decide outcomes more than the compound label does. The sermorelin before and after page works through what those studies do and do not support.

The honest framing is that nobody has run the head to head trial. Every comparison below, including this one, is built by placing two separate evidence bases beside each other, and that is a weaker form of comparison than it looks.

Head to Head on the Practical Numbers

The row worth reading twice is the dose row. Tesamorelin is dosed at roughly seven to ten times the milligram quantity used for sermorelin in clinic practice. Anyone comparing the two on a cost per milligram basis is comparing the wrong number, because the milligrams are not doing equivalent work. The cost per mg index is useful within a compound and misleading across compounds with different dosing scales.

Visceral Fat: The One Endpoint With a Clear Answer

If the goal is visceral adipose tissue specifically, the comparison is not close, and not because sermorelin was measured and lost. Only one of the two has ever been pointed at that endpoint with CT imaging.

Tesamorelin's visceral fat effect is also notably selective. Subcutaneous fat moved far less than visceral fat in the trials, which is unusual and is the main reason the compound found a regulatory niche at all. Visceral adipose tissue is the metabolically active depot, so a drug that preferentially reduces it is doing something more interesting than general fat loss.

The catch is durability. The extension data showed that participants taken off tesamorelin regressed toward their baseline visceral fat, while those kept on it held their reduction. This is maintenance pharmacology, not a reset. Any plan built on a fixed course followed by permanent results is built on a misreading. The tesamorelin before and after page covers the trajectory and the regression in more detail.

Side Effects and Where They Diverge

The adverse event profiles overlap heavily, which is expected from two compounds acting on one receptor. Injection site reactions lead both lists. Arthralgia, peripheral oedema, paraesthesia and carpal tunnel type symptoms appear in both, and all of them are recognisable as consequences of raised IGF-1 and fluid retention rather than anything idiosyncratic to either molecule.

Where they diverge is in how well the frequency is known. Tesamorelin's rates come from controlled trials with placebo arms, which is why figures such as injection site erythema in the high single digits and arthralgia in the low teens can be quoted at all. Sermorelin's reported effects (flushing, headache, dizziness, injection site discomfort) come from clinical observation without a placebo comparison, so the numbers attached to them are impressions rather than rates.

Glucose deserves its own note. Tesamorelin trials recorded a small rise in HbA1c at 26 weeks that had largely normalised by 52 weeks, consistent with a transient effect of raised GH on insulin sensitivity rather than a progressive one. It is still the reason anyone with existing glucose dysregulation has a genuine reason for supervision. The general peptide side effects page covers the class-wide picture, and this page covers how to think about risk when the underlying data is this uneven.

What Neither Compound Does

Both are frequently sold on claims their evidence does not reach.

• Neither is growth hormone. They prompt the pituitary to release its own, which means a functioning pituitary is a prerequisite and the ceiling is set by the gland, not the dose.
• Neither reverses aging. IGF-1 rising is a measurable change, not an outcome. The studies measured surrogate markers, not healthspan.
• Neither builds meaningful muscle on its own. The lean mass changes recorded in sermorelin studies were modest, sex-specific and slow. Anyone expecting an anabolic effect in the sense that word usually carries is going to be disappointed. This comparison covers why.
• Neither has been tested against the other. Worth repeating, because comparison articles including this one create an illusion of direct measurement that does not exist.

Which One Fits Which Goal

Stated as plainly as the evidence allows:

Visceral fat as the specific target. Tesamorelin is the only one with data on that endpoint, and the data is good. The cost and the narrow label are the obstacles, not the evidence.

A general GH axis nudge, sleep quality, recovery, gradual body composition drift. Sermorelin's price and long clinic history make it the default here, with the clear caveat that "default in practice" is not the same as "supported by trials". The sermorelin dosage guide and tesamorelin dosage guide cover protocol specifics for each.

Maximum pituitary response. Neither, alone. Pairing a GHRH analogue with a ghrelin receptor agonist hits two separate receptors and the signals add, which is the logic behind the tesamorelin and ipamorelin stack and the CJC-1295 and ipamorelin pairing. Stacking two GHRH analogues does not work that way, because they compete for the same site.

Unsure which GHRH analogue at all. Ipamorelin against sermorelin is the more common first comparison, and it sits one step earlier in the decision than this one does.

The Research Chemical Caveat

Every figure on this page comes from supervised studies using pharmaceutical grade material at verified concentrations. None of those conditions hold for material bought online, and two failure modes sit entirely outside the data above.

Concentration error is the common one. These two are dosed at scales that differ by nearly a factor of ten, so a reconstitution mistake made while switching between them produces a wrong order of magnitude rather than a slightly wrong dose. The reconstitution guide exists for this reason. Purity is the second, unverifiable without a batch certificate of analysis. Storage handling compounds both, since a degraded vial reads as an ineffective compound rather than a spoiled one.

Frequently Asked Questions

Is tesamorelin stronger than sermorelin?

On duration of signal, yes. Sermorelin clears in roughly 11 to 12 minutes, while tesamorelin survives in circulation for something closer to half an hour because a hexenoyl group on the N-terminus blocks the enzyme that normally cleaves GHRH within minutes. That longer exposure produces a larger IGF-1 response at standard doses. Calling it stronger in any broader sense overstates the case, because the two have never been compared head to head in a trial.

Which is better for belly fat, tesamorelin or sermorelin?

Tesamorelin is the only one of the two with visceral fat as a trial endpoint. Two phase 3 trials at 2mg daily for 26 weeks produced roughly a 15 percent reduction in visceral adipose tissue against a small increase on placebo, which is what the approval rests on. Sermorelin has no comparable visceral fat data. That is a gap in the evidence rather than a demonstrated failure, but it is the gap that matters if visceral fat is the goal.

Why is sermorelin still used if tesamorelin has better data?

Cost and access, mostly. Tesamorelin carries a brand price that runs into thousands of dollars a month, and its approval covers one narrow population. Sermorelin has been compounded for decades, costs a fraction as much per month, and has a long safety record in clinic use even though that record is not the same thing as trial evidence. For anyone whose goal is a general GH axis nudge rather than visceral fat specifically, the price difference does most of the deciding.

Do tesamorelin and sermorelin work the same way?

Yes, at the receptor. Both bind the GHRH receptor on pituitary somatotrophs and prompt the gland to release its own growth hormone in pulses. Neither is growth hormone. Because the pituitary stays in the loop, somatostatin feedback still caps the response, which is the structural reason GHRH analogues do not produce the sustained supraphysiological levels that injected growth hormone can.

Does the visceral fat come back after stopping tesamorelin?

Yes. The 52 week extension data showed that participants moved off tesamorelin regressed toward baseline visceral fat, while those who stayed on it held their reduction. The effect is maintained by continued dosing rather than being a one time reset. Anyone treating a 26 week course as a permanent fix is reading the trials incorrectly.

Can you take tesamorelin and sermorelin together?

There is no reason to. Both compete for the same receptor, so stacking two GHRH analogues mostly means paying twice for one pathway. The combinations with mechanistic logic pair a GHRH analogue with a ghrelin receptor agonist such as ipamorelin, because those act on separate receptors and the two signals add. Two GHRH analogues together do not.